Rate My Professor Angus Jones

Professor Angus Jones is a Professor of Diabetes at the University of Exeter Medical School and an Honorary Consultant Physician in Endocrinology and Diabetes at the Royal Devon University Healthcare NHS Trust. He completed his PhD in 2014 at the Peninsula College of Medicine and Dentistry, a joint institution of the Universities of Exeter and Plymouth. As a clinician-scientist, he merges clinical practice with research dedicated to precision approaches in diabetes management. His efforts have revolutionized diabetes classification by promoting practical use of biomarkers such as C-peptide and islet autoantibodies, alongside clinical prediction models that integrate patient features for accurate subtyping and personalized treatment. Jones developed a quick, low-cost C-peptide test costing £10, which measures endogenous insulin production to differentiate type 1 from type 2 diabetes and other subtypes. This test is now available in seven NHS specialist clinical laboratories, processing over 8,000 referrals per year to the Exeter laboratory alone. His findings have been adopted into major guidelines, including those from NICE, the Association of British Clinical Diabetologists, Canadian national guidelines, and the American Diabetes Association.

Jones directs the University of Exeter NIHR Global Health Group on diabetes in Sub-Saharan Africa, investigating aetiology, optimal diagnosis, monitoring, and management in low-resource settings to build research capacity. He has secured four NIHR career development awards, beginning with an Academic Clinical Fellowship in 2008 and including a Doctoral Research Fellowship that confirmed C-peptide's role in identifying type 2 diabetes patients unresponsive to certain glucose-lowering drugs, as published in Diabetes Care. His innovations extend to prediction models forecasting insulin cessation and stratified therapies for type 2 diabetes using genetics, proteins, and blood biomarkers to anticipate responses to drugs like SGLT2 inhibitors, DPP4 inhibitors, and pioglitazone. Recognized with the 2022 European Foundation for the Study of Diabetes and Novo Nordisk Foundation Precision Diabetes Medicine Award (DKK 2 million), EFSD Rising Star Award, Diabetes UK RD Lawrence Lecture, and Association of British Clinical Diabetologists Niru Goenka Lecture, Jones's work, cited over 5,300 times, profoundly impacts clinical practice, reduces NHS costs, and influences international diabetes care standards.